The GeneASIC Next Generation Sequencing Analysis Acceleration Platform will debut to accelerate early intervention genome sequencing.
LAS VEGASJan. 5, 2022 / PRNewswire / – GeneASIC Technologies will enter CES 2022 this year with its first product, the GeneASIC Next Generation Sequencing Analysis Acceleration Platform (NGSAAP). The annual event is considered the most influential technology event and is a showcase for the latest design and engineering innovations in the consumer technology segment.
GeneASIC NGSAAP is a lightning-fast on-site NGS data analysis solution that provides direct and instant access to rare and common genotypes. The efficient system reduces the time required for data transmission between end users and cloud servers. In addition, as a turnkey on-site solution, the system guarantees data confidentiality and security. GeneASIC NGSAAP achieves this by leveraging the company’s research and development capacity, combined with a pioneering and innovative strategy.
The technology at the heart of the product has advanced beyond conventional slow computing and cloud computing. Secondary analysis of 30X whole genome sequencing (WGS) data from FASTQ to VCF can be completed in 30 minutes. With around six billion nucleotides in the human diploid genome, even a seemingly negligible error rate of 0.01% could mean 600,000 errors throughout the sequence. High coverage ensures that the data is reliable and therefore of clinical quality. While preserving precision, GeneASIC Technologies has succeeded in miniaturizing the tedious sequencing analysis pipeline to a compact size. GeneASIC NGSAAP consumes less power, giving hospitals, general health check-ups and research institutes the power of genomics anytime, anywhere.
All this to accelerate the achievement of precision medicine, a booming field in which many countries have invested and carried out genome projects. Such examples include “Genomics Future of Health Mission” in Australia, “The 100,000 genomes project” UK, “100,000 genomes project” in China, “Over a million genome initiatives“in the EU, and”All of us“in the United States. More recently, the United Kingdom’s NHS and Genomics England have planned to offer parents the option of having a WGS for their newborns through the Newborn Genomes Program which aims to sequence between 100,000 and 200,000 babies.
“This is an opportunity for GeneASIC Technologies to gain a foothold in the UK market through NGSAAP and to contribute to these efforts. Currently, the price of GeneASIC NGSAAP costs half the price of other high-performance computer products for genomic data analysis, ”said Alex lee, director of research and development of GeneASIC Technologies.
The GeneASIC Next Generation Sequencing Analysis Acceleration Platform will be showcased for the first time at the Taiwan Tech Arena (TTA) pavilion at Eureka Park, Venetian Expo 1F (Formerly Sands expo), booth # 61423.
About GeneASIC Technologies
GeneASIC Technologies focuses on hardware-accelerated on-site solutions for the analysis of genomic data. The company aims to provide breakthrough advanced computer products to promote sequencing from rare to routine genomes by leveraging its strong research and development capability. He anticipates that useful sequencing information can be obtained by anyone, anywhere and anytime in the near future.
GeneASIC Technologies is currently developing an analysis acceleration product in USB format for third generation sequencing (also known as long read sequencing). It opens a new round of funding and invites all interested partners to join.
For more information visit https://geneasic.com/.
Copyright © acrofan All rights reserved